MedTrace Logo

A Multiple Ascending Dose Study Evaluating the Safety and Tolerability of a Novel Formulation of QRL-101 in Healthy Participants

NCT07421778 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2026-02-19

No results posted yet for this study

Summary

QRL-101-08 is a multiple ascending dose (MAD) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of a novel formulation of QRL-101 in healthy participants.

Conditions

  • Healthy Participant Study

Interventions

DRUG

QRL-101

Multiple-ascending doses of QRL-101 will be orally administered to healthy participants.

DRUG

Placebo

Multiple-ascending doses of comparator placebo will be administered orally to healthy participants.

Sponsors & Collaborators

  • QurAlis Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-02
Primary Completion
2026-08-31
Completion
2026-08-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07421778 on ClinicalTrials.gov